Figure 5.
MRD/ctDNA recurrences after end of treatment. All patients with MRD recurrence after or at the end of treatment by either FCM and/or ctDNA are shown, including patients with MRD recurrence and subsequent clinical disease progression. Each horizontal bar represents 1 patient (blue: prior exposure to BTK inhibitors and/or venetoclax; green: no prior BTK inhibitor/venetoclax) and starts at the end of study treatment (ie, time point 0 on the x-axis); that is, all MRD recurrences listed here occurred after study treatment was discontinued. Patients are grouped according to the method that first detected the MRD recurrence. The length of the bars shows the observation time for each patient between the end of treatment and the last available staging in months. The time points of ctDNA recurrence, FCM MRD recurrence, and clinical disease progression are shown for each patient if applicable. To clearly show the difference between FCM-based MRD recurrence and ctDNA recurrence, only the first positive results for each method are shown. Positive ctDNA or FCM results (ie, recurrences) that are followed by multiple negative results using the same method are not counted as MRD/ctDNA recurrences to reduce the risk of false-positive detection of molecular relapses. In the supplement, tables detailing all MRD/ctDNA results for each individual patient are shown. For each patient, certain clinical and genetic characteristics are shown on the left of the y-axis, next to the corresponding horizontal bar. Bulky disease was defined as at least 1 lymph node ≥5 cm in diameter on baseline computed tomography imaging. Benda, bendamustine; CKT, complex karyotype; Del(11q), deletion 11q; Del(13q), deletion 13q; Del(17p), deletion 17p; hCKT, highly complex karyotype; ven, venetoclax.

MRD/ctDNA recurrences after end of treatment. All patients with MRD recurrence after or at the end of treatment by either FCM and/or ctDNA are shown, including patients with MRD recurrence and subsequent clinical disease progression. Each horizontal bar represents 1 patient (blue: prior exposure to BTK inhibitors and/or venetoclax; green: no prior BTK inhibitor/venetoclax) and starts at the end of study treatment (ie, time point 0 on the x-axis); that is, all MRD recurrences listed here occurred after study treatment was discontinued. Patients are grouped according to the method that first detected the MRD recurrence. The length of the bars shows the observation time for each patient between the end of treatment and the last available staging in months. The time points of ctDNA recurrence, FCM MRD recurrence, and clinical disease progression are shown for each patient if applicable. To clearly show the difference between FCM-based MRD recurrence and ctDNA recurrence, only the first positive results for each method are shown. Positive ctDNA or FCM results (ie, recurrences) that are followed by multiple negative results using the same method are not counted as MRD/ctDNA recurrences to reduce the risk of false-positive detection of molecular relapses. In the supplement, tables detailing all MRD/ctDNA results for each individual patient are shown. For each patient, certain clinical and genetic characteristics are shown on the left of the y-axis, next to the corresponding horizontal bar. Bulky disease was defined as at least 1 lymph node ≥5 cm in diameter on baseline computed tomography imaging. Benda, bendamustine; CKT, complex karyotype; Del(11q), deletion 11q; Del(13q), deletion 13q; Del(17p), deletion 17p; hCKT, highly complex karyotype; ven, venetoclax.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal